Merck & Co. said Monday it will acquire Cubist Pharmaceuticals Inc. for $8.4 billion. The transaction will include $1.1 billion in net debt (based on projected cash balances) and other considerations for a total transaction value of about $9.5 billion.
GlaxoSmithKline PLC (GSK) has reversed a plan to possibly sell some of its established drugs in order to focus on fast-growing medications.
Jeremy Levin has resigned as chief executive officer at Teva Pharmaceutical Industries Ltd. and has been replaced on an interim basis by finance chief Eyal Desheh.
Crossmark has named former GlaxoSmithKline PLC (GSK) executive Janet Carter Smith as vice president of business development. In her new role, Carter Smith will focus on working with new client opportunities across the company’s portfolio of services.
With this year’s Medicare Part D registration period overlapping with open enrollment for the new health insurance marketplaces, Walgreen Co. has recognized a growing need to help Medicare beneficiaries understand their drug coverage options.
Rexall Pharma Plus is partnering with Rochester, N.Y.-based PharmaSmart International Inc. on medication therapy management. The alliance integrates PharmaSmart interoperable biometric screening technology with Rexall’s dispensing system.
Walgreen Co. and Alliance Boots GmbH have named Alex Gourlay, chief executive officer of the health and beauty division, Alliance Boots, as a Walgreens executive vice president and president of customer experience and daily living, effective October 1.
Walgreen Co. and CVS Caremark Corp. are conducting outreach campaigns to educate consumers about health insurance options under the Affordable Care Act. CVS Caremark’s effort will include in-store events, brochure displays and online information at cvs.com/insurance.
No one in 1997 would have predicted that Josh Flum would become one of the most important pharmacy executives in the country. That year he graduated from Yale Law School and started on a journey that took him from the U.S. Court of Appeals for the Third Circuit, where he served as
NEHI has issued a report highlighting what it terms six “priorities for action” to improve patient medication adherence. The report underlines the importance of increasing awareness of medication therapy management (MTM).
In a move that industry insiders see as a possible prelude to spinning off its generics drug business, Pfizer Inc. said it plans to separate its commercial operations into two units mainly for patent-protected branded treatments and a third for generics.
Perrigo Co. is acquiring Elan Corp., an Irish pharmaceutical firm, for $8.6 billion in a transaction that should give the manufacturer of over-the-counter drugs a low tax base for international expansion.
Walgreen Co. and the Department of Health and Human Services (HHS) have joined forces to develop a medication therapy management (MTM) program to help improve outcomes for HIV patients.
Walmart on Tuesday launched a private label diabetes care line that it said could save U.S. patients up to $60 million annually. The ReliOn products promise an affordable, quality option to help the country’s nearly 26 million individuals with diabetes. The ReliOn Prime meter is priced at $16.
The Supreme Court has ruled that Novo Nordisk’s description of the patent for Prandin, its diabetes drug, is too broad. This decision enables generic drug manufacturer Caraco Pharmaceuticals to sue the innovator company in an effort to force Novo Nordisk to narrow its patent description.
